Short answer
Coherus Oncology, Inc. (CHRS) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results for quarter ended June 30, 2026.
Coherus Oncology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Press release issued August 5, 2026
- Detailed results and management commentary furnished in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Q2 LOQTORZI revenue $13.6M, up 15% sequentially and 37% year over year, supporting continued commercial growth
- Q2 net revenue $14.3M versus $10.3M; GAAP continuing-operations loss narrowed to $33.3M from $44.9M
- Cash, equivalents and marketable securities fell to $105.3M from $172.1M at December 31, 2025
- Operating cash burn reached $120.0M in the first half, heightening future financing risk
- October 2026 data disclosure and 2H 2026 readouts represent key catalysts for tagmokitug and casdozokitug valuation
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Coherus Oncology, Inc. 8-K filings
Get the next CHRS 8-K as it lands
Follow CHRS for push alerts, or ask the research agent what this filing means.